Reviewing Acorda Therapeutics (NASDAQ:ACOR) and CytRx (CYTR)

Share on StockTwits

Acorda Therapeutics (NASDAQ:ACOR) and CytRx (NASDAQ:CYTR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.


This table compares Acorda Therapeutics and CytRx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics -1.40% 9.34% 4.37%
CytRx N/A -29.54% -20.17%

Institutional & Insider Ownership

9.8% of CytRx shares are held by institutional investors. 7.1% of Acorda Therapeutics shares are held by company insiders. Comparatively, 6.6% of CytRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Acorda Therapeutics and CytRx’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acorda Therapeutics $471.43 million 1.13 $33.68 million $1.82 6.05
CytRx $250,000.00 75.35 -$12.71 million ($0.29) -1.93

Acorda Therapeutics has higher revenue and earnings than CytRx. CytRx is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Acorda Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, CytRx has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Acorda Therapeutics and CytRx, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acorda Therapeutics 2 5 2 0 2.00
CytRx 0 0 1 0 3.00

Acorda Therapeutics currently has a consensus price target of $21.25, suggesting a potential upside of 92.83%. CytRx has a consensus price target of $5.00, suggesting a potential upside of 792.86%. Given CytRx’s stronger consensus rating and higher probable upside, analysts plainly believe CytRx is more favorable than Acorda Therapeutics.


Acorda Therapeutics beats CytRx on 8 of the 14 factors compared between the two stocks.

About Acorda Therapeutics

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

About CytRx

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with's FREE daily email newsletter.